Draft:Alpha Teknova

Alpha Teknova is an American biotechnology company based in California, specializing in the supply of essential reagents for the

Alpha Teknova

Company type	Public
Industry	Health Care/Life Sciences
Founded	1996
Founder	Ted Davis
Area served	Worldwide
Key people	Ted Davis (Founder, Director) Stephen Gunstream (President and CEO) Matthew Lowell (Chief Financial Officer) Damon Terrill (General Counsel and Chief Compliance Officer) Jennifer Henry (Senior Vice President of Marketing)
Products	Agar Plates, Microbial Culture Media, Bacterial Culture Media, Yeast And Fungal, Buffers and Reagents, Dry Powders, PCR Certified Water, Reagent Grade Water, WFI Quality Water, AAV•Tek AEX Buffer Screening Kit, AAV•Tek PCR Sample Prep Kit, AAV•Tek AAV Stabilizer
Revenue	US$36.684 million (2023)
Net income	-US$36.78 million (2023)
Total assets	US$ 128.587 million (2023)
Total equity	US$90.036 million (2023)
Number of employees	211
Website	https://teknova.com

production of biopharmaceutical products. The company's patented technologies facilitate the development and delivery of custom products, including reagents and materials for bioprocessing, biomanufacturing, and molecular diagnostics. These products include cell culture media, protein and nucleic acid purification kits, and reagents used in gene therapy, mRNA therapy, genomics, and synthetic biology.

History

Alpha Teknova was founded in 1996 by Ted Davis, a former scientist at Genentech, in Half Moon Bay, California. Before establishing the company, Davis served as the Director of Consumables at Genomyx Inc., a company founded within Genentech. Until May 2020, he held the positions of President, CEO, and Chief Scientific Officer at Alpha Teknova. Ted Davis currently serves on the company's Board of Directors.

In 2017, the company began the process of certifying its quality management system for medical devices to comply with ISO 13485:2016 standards. The certification was obtained on April 8, 2023, and is valid until July 25, 2026.

Alpha Teknova went public with an initial public offering (IPO) on June 25, 2021. On December 15 of the same year, it was added to the Nasdaq Biotechnology Index.

In August 2023, the company opened a new modular Good Manufacturing Practice (GMP)-certified manufacturing facility in Hollister, California. This expansion increased the site to more than 200,000 square feet, enhancing its production capacity and adding modern capabilities.

Industries and Products

Alpha Teknova serves several key areas in biotechnology:

• Bioproducts: Supplies reagents and materials for gene therapy, vaccine development, plasmid production, monoclonal antibodies (mAbs), and cell therapy.
• Molecular Diagnostics: Offers products for the amplification, extraction, sequencing, and analysis of DNA and RNA. This includes buffers and enzymes for reverse transcription (RT) and products for protein expression and analysis.
• Synthetic Biology: Provides culture media and agar plates for the growth of microorganisms and modified yeasts, as well as systems for culturing and maintaining mammalian cell lines.

Recent Developments

• September 27, 2023: Launched the latest version of its patented AAV-Tek™ AEX buffer screening kit for serotype identification of AAV6, along with a reagent kit to support each stage of the plasmid manufacturing process.
• May 7, 2024: Introduced Build-Tek™ Solutions, a customizable product configurator designed to meet the need for rapid recovery using high-quality buffers during the early stages of therapy development. Also announced the availability of the newest product from its AAV-Tek™ Solutions line—the AAV-Tek stabilizer—which enhances recovery and protects the integrity of capsids throughout the purification process.
• August 16, 2024: Launched two new products: Express-Tek™, which allows customers to bring their products to market in days instead of weeks, significantly reducing lead times; and RUO+, which enables customers to scale efficiently from discovery through process development into clinical manufacturing.